Successful treatment with rituximab of one patient with CANOMAD neuropathy

J Neurol. 2010 Apr;257(4):655-7. doi: 10.1007/s00415-009-5412-z. Epub 2009 Dec 4.

Abstract

We report a successful treatment with rituximab in a patient with CANOMAD neuropathy resistant to previous therapy. The titers of anti-disialosyl antibodies were decreased 3 months after the beginning of the treatment and the sensory ataxia clearly improved after 9 months of therapy.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Anemia, Hemolytic, Autoimmune / complications
  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, Surface / immunology
  • Female
  • Humans
  • Immunoglobulin M / blood
  • Immunologic Factors / therapeutic use*
  • Oligosaccharides / immunology
  • Ophthalmoplegia / complications
  • Ophthalmoplegia / drug therapy*
  • Polyradiculoneuropathy / complications
  • Polyradiculoneuropathy / drug therapy*
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, Surface
  • Immunoglobulin M
  • Immunologic Factors
  • Oligosaccharides
  • disialosyl-T antigen, human
  • Rituximab